NASDAQ:CYTT Cyteir Therapeutics (CYTT) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free CYTT Stock Alerts $3.01 -0.01 (-0.33%) (As of 03/18/2024) Add Compare Share Share Today's Range$2.92▼$3.1950-Day Range N/A52-Week Range$1.65▼$3.19Volume551,300 shsAverage VolumeN/AMarket Capitalization$108.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsSocial MediaStock AnalysisChartEarningsFinancialsSEC FilingsSocial Media Get Cyteir Therapeutics alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Cyteir TherapeuticsCyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.Read More CYTT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTT Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive CYTT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyteir Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTT CUSIPN/A CIK1662244 Webcyteir.com Phone857-285-4140FaxN/AEmployees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-24.88% Return on Assets-23.83% Debt Debt-to-Equity RatioN/A Current Ratio21.89 Quick Ratio21.89 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.13 per share Price / Book0.73Miscellaneous Outstanding Shares36,000,000Free Float30,814,000Market Cap$108.36 million OptionableN/A Beta0.08 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Joseph S. Zakrzewski (Age 62)Independent Investor & Independent Chairman of the Board Comp: $81.5kDr. Markus F. Renschler M.D. (Age 63)President, CEO & Director Comp: $718.62kDr. Kevin Mills Ph.D.Co-FounderMr. David G. Gaiero (Age 46)CFO & Treasurer Key CompetitorsNuvectis PharmaNASDAQ:NVCTRezoluteNASDAQ:RZLTRelmada TherapeuticsNASDAQ:RLMDCytomX TherapeuticsNASDAQ:CTMXAbeona TherapeuticsNASDAQ:ABEOView All Competitors CYTT Stock Analysis - Frequently Asked Questions How have CYTT shares performed in 2024? Cyteir Therapeutics' stock was trading at $3.01 at the start of the year. Since then, CYTT stock has increased by 0.0% and is now trading at $3.01. View the best growth stocks for 2024 here. How do I buy shares of Cyteir Therapeutics? Shares of CYTT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTT) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldUrgent Nvidia WarningAltimetryAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldGold ManiaStansberry ResearchThe Gold Grab of the CenturyColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyteir Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.